Acute Myeloid Leukemia (AML) Frontline Panel
Use
FISH panel test on hematologic specimens for the most commonly observed abnormalities in acute myeloid leukemia (AML). The test includes the detection of chromosome abnormalities such as deletions in 5 and 5q, 7 and 7q, and rearrangements including the RUNX1::RUNX1T1 fusion, CBFB, and KMT2A rearrangements. It is frequently ordered in conjunction with the AML Secondary Panel to provide a comprehensive analysis of genetic aberrations commonly associated with AML.
Special Instructions
All attempts will be made to process and report samples received > 72 hours post-collection. Bone marrow is the sample of choice in most hematologic malignancies.
Limitations
The test is designed for the detection of specific chromosome abnormalities associated with acute myeloid leukemia. It may not identify all genetic abnormalities present in AML cases. Stated turn-around-times (TATs) are subject to change based on biopharma protocol requirements and will be specified in the biopharma study contract. Results may be affected if specimens are clotted, exposed to extreme temperatures, or contain anticoagulants toxic to cells.
Methodology
Chromosomal / Cytogenetics (FISH)
Biomarkers
Result Turnaround Time
5 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5 mL
Minimum Volume
Not provided
Container
EDTA preferred (NaHep accepted)
Storage Instructions
2°C to 25°C
Causes for Rejection
Clotted specimen; Specimen exposed to extreme temperature; Anticoagulant toxic to cells; Insufficient number of cells
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 72 hours |